Navigation Links
MPM Capital Leads Investment in Proteon Therapeutics
Date:3/5/2009

Dr. Steven St. Peter Named to Proteon Board of Directors

KANSAS CITY, Mo., March 5 /PRNewswire/ -- MPM Capital, one of the world's largest life sciences-dedicated venture capital investors, announced today that it is the lead investor in a $38 million Series B equity financing of Proteon Therapeutics. In addition, Dr. Steven St. Peter, Managing Director of MPM Capital, has been named to the Proteon Therapeutics Board of Directors.

Proteon recently initiated a Phase 1/2 clinical trial of its lead product, PRT-201. PRT-201 is a recombinant human elastase that is being studied for its ability to improve arteriovenous fistula (AVF) surgery outcomes in patients requiring chronic hemodialysis.

"MPM continues to be very impressed with Proteon and the progress that the company has made," said Dr. Steven St. Peter. "In addition, this marks the first investment by MPM in a company with a substantial Kansas City presence. We have long followed the positive developments in the Kansas City area life sciences sector, and this investment affirms our view that attractive opportunities originate there."

Over the last several years, Dr. Steven St. Peter has worked informally with the Kansas City Area Life Sciences Institute in an advisory capacity. In addition, he currently serves as a member of the Kansas Bioscience Authority's Heartland BioVentures Advisory Board. Originally from Wichita, Dr. St. Peter has a B.A. in Chemistry from the University of Kansas. He completed his Doctor of Medicine at Washington University in St. Louis and his residency and fellowship at the Hospital of the University of Pennsylvania.

"Proteon is very pleased to have attracted the interest of MPM Capital, one of the world's premier healthcare venture capital firms," said F. Nicholas Franano, M.D., Chief Scientific Officer and founder of Proteon Therapeutics. "MPM's understanding of the life sciences industry makes them an ideal investor. In addition, I have known and worked with Steven St. Peter for over 20 years and am excited about the contribution he will make to our board of directors and the future direction of our company."

In addition to MPM Capital, the other new investor in this round of financing is the Vectis Healthcare & Life Sciences Fund. MPM and Vectis have a strong and deep relationship.

Tim Noyes, CEO of Proteon, said, "Proteon welcomes these additions to our already strong investor base. This financing will allow us to fund very significant clinical development in a field that needs better solutions."

About MPM Capital

MPM Capital is one of the world's largest dedicated investors in the life sciences. With offices in Boston and San Francisco, the firm manages committed capital in excess of $2 billion. MPM Capital has a deep and experienced team capable of investing from early-stage to late-stage which positions it to invest across the full spectrum of healthcare innovation. For additional information, visit www.mpmcapital.com

About Proteon Therapeutics

Proteon Therapeutics, Inc. is a privately held biopharmaceutical company developing novel, first-in-class pharmaceuticals to address the critical medical needs of patients with kidney and vascular diseases. The company is headquartered in Waltham, Mass., and has research facilities in Kansas City, Mo. For additional information, visit www.proteontherapeutics.com


'/>"/>
SOURCE MPM Capital
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Matrixx Initiatives, Inc. to Present at the Roth Capital Partners 2007 New York Conference
2. AtriCure to Present at Roth Capital Partners 2007 New York Conference
3. Doctors and medical ethicist discuss whether doctors should participate in capital punishment
4. Doctors and Medical Ethicist Discuss Whether Doctors Should Participate in Capital Punishment
5. Osteotech to Present at First Albany Capitals Regenerative Technologies Conference in New York
6. iCAD to Present at Americas Growth Capital 4th Annual Emerging Growth Conference
7. Pharsight Files Application for Nasdaq Capital Market Listing
8. Advanced Life Sciences Joins NASDAQ Capital Market
9. Foundation Venture Capital Group, LLC Invests in Start Up Committed to Breast Cancer Diagnostics
10. Bally Total Fitness Emerges From Chapter 11 and Closes Transaction with Harbinger Capital Partners Funds
11. Caxton-Iseman Capital Acquires Conney Safety Products, LLC
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/25/2016)... ... May 25, 2016 , ... TransactRx announces the release ... of medical service claims by Pharmacy Benefit Managers that were submitted by Retail ... The TransactRx Cross Benefit Clearinghouse receives standard professional medical claims submitted from the ...
(Date:5/25/2016)... ... , ... America Walks , a national advocacy organization that promotes walking ... of Pittsburgh Graduate School of Public Health , has been awarded a Walking ... from around the country to participate in a four-month training program designed to strengthen ...
(Date:5/25/2016)... (PRWEB) , ... May 25, 2016 , ... ... health insurance, has seen a significant spike in their clients' employee participation for ... annual biometric health screening by implementing a high-deductible health plan with outcome-based deductible ...
(Date:5/25/2016)... ... May 25, 2016 , ... HealthPostures , a national ... leading engineers at the American Society of Safety Engineers Conference in Atlanta, Georgia. ... , Engineers, speakers and exhibitors from more than 40 countries are scheduled to ...
(Date:5/24/2016)... ... 2016 , ... Sterling Global Products is launching a Kickstarter campaign focused on ... dispenser. The campaign kick-off video is located via this link https://youtu.be/WsO4qz2odco . The ... is to raise $1,000 per day for a total of $25,000. The funds will ...
Breaking Medicine News(10 mins):
(Date:5/24/2016)... , May 24, 2016 ... médica para ayudar a los médicos a compartir sus ... pacientes a escala mundial. Profesionales médicos de Europa, África, ... se han apuntado a la aplicación, que combina la ... un entorno totalmente seguro. Educación   ...
(Date:5/24/2016)...   , Study met ... and superiority in , Excellent plus ... of the ascending colon   , ... B.V. today announced new positive data from the phase III MORA ... standard 2 litre PEG with ascorbate. The study met both primary ...
(Date:5/24/2016)... , May 24, 2016 ARANZ ... for the healthcare sector, has been named the Coretex Hi-Tech ... Awards 2016. Dr Bruce Davey , CEO ... our team.  It,s really good to be recognised for the ... Our products are used in 35 countries around the world ...
Breaking Medicine Technology: